BioSpace News Archive

CLS Holdings USA, Inc. (OTCQB:CLSH)(CSE:CLSH), the ''Company’’ or ''CLS’’, a diversified cannabis company operating as Cannabis Life Sciences, today announced its participation at the 2020 Virtual US Cannabis Symposium presented by Canaccord Genuity on September 30, 2020.

CSL Behring, a global biotherapeutics leader, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in patients 6 years of age and older.

EmblemHealth, one of the nation’s largest nonprofit health insurers, released results of a new study that found that nearly half of New Yorkers will be more likely to get a flu vaccination this fall due to the ongoing coronavirus pandemic.

PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), today announced that its Chief Medical Officer, Lauren V. Wood, M.D. will present key data from the company’s previously reported Phase 1 trial of PDS0101

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the Company will be exhibiting and showcasing new data at the Heart Failure Society of America’s (HFSA) Virtual Annual Scientific Meeting 2020 taking place from September 30th - October 6th, 2020. The Company will host a booth and will be available online throughout the e

Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, will host a two-part “5G Insights” webinar series on October 6 and 8, 2020. The educational webinars will include industry experts who will discuss the evolution from 1G to 5G, drivers of 5G adoption, the continued role of 4G, next-generation Wi-Fi and the technologies that

Varex Imaging Corporation (Nasdaq: VREX) today announced it has priced a private offering (the “Offering”) of $300 million aggregate principal amount of 7.875% senior secured notes due 2027 (the “notes”) at an offering price of 100% of the principal amount thereof

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has re-activated study sites and recommenced patient recruitment in a Phase 2 study of NYX-2925 in patients with fibromyalgia.

Jaguar Health, Inc. (NASDAQ:JAGX) announced today that the company’s wholly owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), is a proud sponsor of this year’s National Trans Visibility March (NTVM), a week-long virtual event beginning September 28, 2020.

Immunic, Inc. announced the results of a pre-planned interim safety analysis and a recruitment update from the ongoing phase 2 CALVID-1 trial of its selective oral DHODH inhibitor, IMU-838, in patients with moderate coronavirus disease 2019.